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Introduction
Methylmalonic aciduria (MMA) comprises a heteroge-
neous group of disorders, which are characterized by
accumulation of methylmalonate in the body due to
deficiency of methylmalonyl coenzyme A mutase
(MCM, EC 5.4.99.2) or defects in the uptake, trans-
port or synthesis of 5’-deoxyadenosylcobalamin, the
cofactor for MCM.1,2 Clinical manifestations of classical
MMA include metabolic acidosis, lethargy, vomiting,
dehydration, hepatomegaly, hyperammonemia, neu-
rological deterioration, and hypotonia.3 Patients with
mut0 (undetected MCM activity) have the worst prog-
nosis. Most of these patients might have very-early-
onset signs and symptoms that occur even before the
results of newborn screening (NBS) are available, and
die immediately or survive with significant neurode-
velopmental disability.4–6
Because of the fulminant clinical course of MMA
in neonates, emergency treatment such as energy 
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supply management, antibiotics or even hemodialysis
is usually necessary to save lives. Therefore, immediate
differentiation of affected from unaffected neonates
when there are abnormal results in MMA NBS is very
important. However, the results of confirmatory tests
such as urinary organic acid analysis, mutation analy-
sis, or repeated tandem mass spectrometry (MS/MS)
are usually not available immediately during such
emergencies.
Therefore, we wanted to establish if there were any
differences between affected and unaffected newborns
by comparing the initial screening results with routine
biochemical data when the newborns were referred to
confirmatory medical centers. Here, we report the
experience of 7 years of NBS for MMA in Taiwan, to
establish if we can make an immediate accurate diag-
nosis of MMA by analyzing the initial laboratory data
of these newborns.
Methods
Between January 2002 and December 2008, 598,522
newborns were screened for MMA using dried blood
spots (DBSs) by MS/MS at the Chinese Foundation
of Health and the Taipei Institute of Pathology. DBSs
were obtained from newborns after 48–72 hours of
life and 24–48 hours of feeding. The DBSs were ana-
lyzed by the Micromass Quattro Micro API Mass
Spectrometer (Waters Corp., Milford, MA, USA) 
or PerkinElmer MS/MS System (PerkinElmer Inc.,
Waltham, MA, USA). The levels of propionylcarnitine
(C3) and acetylcarnitine (C2) were measured during
MMA screening. The cut-off (borderline) values were
set at > 7 μM for C3 and > 0.25 for C3/C2 ratio at the
Chinese Foundation of Health, and > 6 μM for C3 and
> 0.2 for C3/C2 ratio at the Taipei Institute of Pa-
thology. The positive cut-off values were established
at > 10 μM for C3 and > 0.5 for C3/C2 ratio at both
centers. If a screening result was greater than or equal
to the positive cut-off value, the newborn was referred
immediately to a confirmatory medical center. If a
screening result was greater than or equal to the border-
line cut-off, but less than the positive cut-off, repeat
blood sampling was requested. When the second test
was still outside the normal range, the newborn was
referred to a confirmatory medical center.
After admission to the confirmatory referral centers,
plasma ammonia, plasma amino acid analysis, urine
organic acid analysis, liver function tests, and blood gas
analysis were performed. MCM enzyme activity and
mutation analysis were performed when MMA was
found by urinary organic acid analysis.
The referred newborns were divided into a true-
positive group (affected) and a false-positive group
(unaffected). The affected group was defined by pres-
ence of methylmalonic acid by urine organic acid
analysis, with decreased MCM activity by enzyme assay.
The unaffected group was defined by normal urine
organic acid analysis without abnormal clinical mani-
festations. Initial C3 level, C3/C2 ratio, plasma ammo-
nia, liver function tests, blood pH and bicarbonate
from blood gas analysis, gestational age, and percentile
of birth body weight (BBW) were compared between
the 2 groups. Categorical data were analyzed by Fisher’s
exact test, and continuous data by Mann–Whitney U
test. A p value < 0.05 was of statistical significance. The
statistical software package used was SPSS version
15.0 (SPSS Inc., Chicago, IL, USA).
Results
Among the 598,522 newborns screened by the 2 cen-
ters in the 7-year period, 22 patients were referred.
Seven of these were confirmed to have mut0 MMA with
undetected MCM activity, and the mutation analysis in
4 patients was: c.323G > A/c.1741C > T, c.1280G >
A/c.1280G > A, c.1280G > A/c.754_755insA, and
c.982C > T/c.982C > T. The other 3 patients were
admitted to other hospitals, so the results of mutation
analysis were not available. All of our affected patients
were found to have hyperglycinemia by plasma amino
acid analysis, with a huge peak of methylmalonic acid
by urine organic acid analysis. Two of 15 unaffected
newborns were admitted to other hospitals (due to
personal reasons); therefore, the data from these 2
newborns were not available. All of the 7 MMA pa-
tients already had metabolic decompensation when
they were admitted to the confirmatory medical cen-
ters. Their clinical manifestations included poor activ-
ity, poor appetite, vomiting, and shortness of breath.
Out of 13 unaffected newborns, only 1 was found to
have poor activity and feeding; later, she was diag-
nosed with sepsis, with Staphylococcus sciuri in blood
culture.
The initial screening results of the above 7 patients
and their routine biochemical data are briefly summa-
rized in Table 1. Gestational age, BBW, initial C3
level, C3/C2 ratio, plasma ammonia, liver function
tests, blood gas pH and bicarbonate level were ana-
lyzed in the affected and unaffected groups (Table 2).
All results showed significant differences except for
gestational age, BBW, initial C3 levels and alanine
aminotransferase (ALT). However, when the BBW of
these newborns was adjusted to percentile of BBW,
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the unaffected group had a significantly higher per-
centile than the affected group (p = 0.001).
Discussion
The incidence of MMA in Taiwan, based on MS/MS
NBS of 598,522 infants over a 7-year period, was ap-
proximately 1 in 85,000, which is slightly lower than
that in Japan (∼1 in 50,000 newborns), but signifi-
cantly higher than that in Germany (∼1 in 250,000
newborns).7,8 About one third of referred newborns
were confirmed to have MMA in our MS/MS NBS
program.
C3 is a universal primary marker for MMA screen-
ing. It alone is sensitive enough to detect classical-type
MMA, but lacks 100% sensitivity for milder forms 
of MMA or defects of cobalamin metabolism.9,10
Furthermore, C3 is one of the most frequent analytes
found to be responsible for false-positive results in
MS/MS screening.11 To improve specificity and sen-
sitivity, the C3/C2 ratio usually has been used as a
secondary parameter.9 Our study revealed that C3/C2
ratio was much more reliable than C3 in differentiat-
ing the affected from the unaffected newborns. There
was an overlap of C3 levels, but no overlap of C3/C2
ratio between the 2 groups (Figure 1). All of the af-
fected patients were found to have a C3/C2 ratio >0.4,
Table 1. Laboratory characteristics of the affected group with methylmalonic aciduria
Normal
Range of the 
values
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 false-positive 
group
C3 (μmol/L) < 7 19.18 12.44 16.65 12.39 7.7 10.1 14.9 8.2–22.6
C3/C2 ratio < 0.25 1.18 0.81 0.58 1.13 0.546 0.55 0.627 0.12–0.387
Ammonia 90–150 239 427 465 344 632 695 488 35–125
(μg/dL)
Blood gas pH 7.31–7.41 7.299 7.292 7.468 7.23 7.17 7.374 7.41 7.305–7.564
Bicarbonate 16–24 12.3 10.3 20.3 19.7 9.7 13.9 17.1 14–24.5
(mmol/L)
AST (IU/L) 15–60 31 44 113 135 191 47 59 19–77
ALT (IU/L) 1–25 20 21 32 34 27 9 25 6–94
C3 = propionylcarnitine; C2 = acetylcarnitine; AST = aspartate aminotransferase; ALT = alanine aminotransferase.
Table 2. Statistical comparison between affected and unaffected newborns
MMA n Mean ± SD p
GA (d) No 15 261.47 ± 26.15 0.670
Yes 7 270.00 ± 9.75
BBW (g) No 15 3,256.67 ± 1,021.33 0.062
Yes 7 2,817.86 ± 131.93
C3 (μmol/L) No 15 11.55 ± 3.66 0.217
Yes 7 13.34 ± 3.91
C3/C2 ratio No 15 0.26 ± 0.08 < 0.0001
Yes 7 0.77 ± 0.28
Ammonia (μg/dL) No 13 63.00 ± 23.72 < 0.0001
Yes 7 470.00 ± 157.22
Blood gas pH No 13 7.44 ± 0.08 0.029
Yes 7 7.32 ± 0.10
Bicarbonate (mmol/L) No 13 19.21 ± 3.27 0.019
Yes 7 14.76 ± 4.34
AST (IU/L) No 13 35.31 ± 15.11 0.005
Yes 7 88.57 ± 59.37
ALT (IU/L) No 13 20.23 ± 23.46 0.081
Yes 7 24.00 ± 8.41
MMA = methylmalonic aciduria; SD = standard deviation; GA = gestational age; BBW = birth body weight; C3 = propionylcarnitine; C2 = acetylcarnitine;
AST = aspartate aminotransferase; ALT = alanine aminotransferase.
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and all the unaffected patients were found to have a
ratio < 0.4. In our MMA screening program, the cut-
off values for C3/C2 ratio in our 2 NBS centers were
0.2 and 0.25, respectively. Ten unaffected newborns
would have been referred and no affected patient would
have been missed if we had only used C3/C2 ratio as
the primary parameter. In the MMA screening pro-
gram in Germany, the cut-off value for the C3/C2
ratio was set at 0.39.8 If we had used the German cut-
off, none of the affected patients would have been
missed (all patients’ C3/C2 ratios were > 0.5) and
none of the unaffected newborns would have been
picked up and referred. This could reduce the num-
ber of laboratory analyses, personnel costs for repeat
tests, and considerable anxiety for parents. Therefore,
we believe that we should reevaluate whether or not
C3/C2 ratio could replace C3 as the primary parameter
in our MMA NBS.
In patients with MMA, the accumulation of propi-
onyl coenzyme A could inhibit the activity of N-
acetylglutamate synthetase and then decrease the
synthesis of N-acetylglutamate, which is a natural
activator of carbamyl phosphate synthetase.12 There-
fore, it is not surprising that plasma ammonia levels in
the affected group were significantly higher than in
the unaffected group (Figure 1). All of the affected
patients were found to have a plasma ammonia level
> 200 μg/dL, and all the unaffected patients were
found to have a level < 200 μg/dL. There was no
overlap between the affected and unaffected groups;
therefore, plasma ammonia level was a good parame-
ter to differentiate the affected from the unaffected
newborns.
Due to the accumulation of a lot of organic acids in
patients with MMA, it seems to be reasonable that the
affected group had lower blood gas pH and bicarbonate
levels than the unaffected group. However, because
there was still some overlap between the 2 groups for
these parameters, we do not think that these parameters
are good enough for initial differentiation in MMA
screening.
For comparison of liver function, aspartate amino-
transferase (AST) levels of the affected group were sig-
nificant higher than those of the unaffected group,
but ALT levels were not (Figures 2 and 3). It is well
known that different types of liver injury can increase
the levels of ALT and AST to different ratios. For
example, in viral hepatitis, the AST/ALT ratio is 
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Figure 1. Comparison of (A) propionylcarnitine (C3)/acetylcarni-
tine (C2) ratio, (B) C3 and (C) plasma ammonia concentrations
between unaffected and affected groups.
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usually < 1, but in alcoholic hepatitis, the ratio is usually
> 1. This reminds us that some metabolites in MMA
could perhaps cause injury to liver cells in a similar
manner as alcohol or toxins.
There was no significant difference in gestational
age between the affected and unaffected groups. How-
ever, the affected group had a significantly lower per-
centile of BBW than the unaffected group did. This
suggests that there might be a certain level of prenatal
effect of these metabolic inborn errors in fetuses in the
affected group. However, in light of the small number
of observations in this study, we cannot draw any con-
clusions, and more data are needed to prove the rela-
tionship between low BBW percentile and patients with
MMA.
In conclusion, the referred newborns with elevated
plasma C3/C2 ratios >0.4 or ammonia levels >200μg/
dL are highly suspected of having MMA. Emergency
management should be established immediately to
ensure a better prognosis.
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Figure 2. Comparison of aspartate aminotransferase (AST) con-
centrations between unaffected and affected groups.
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Figure 3. Comparison of alanine aminotransferase (ALT) concen-
trations between unaffected and affected groups.
